Petros Pharmaceuticals Correlations
PTPI Stock | USD 0.49 0.02 4.26% |
The current 90-days correlation between Petros Pharmaceuticals and Ideaya Biosciences is -0.03 (i.e., Good diversification). The correlation of Petros Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Petros Pharmaceuticals Correlation With Market
Average diversification
The correlation between Petros Pharmaceuticals and NYA is 0.14 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Petros Pharmaceuticals and NYA in the same portfolio, assuming nothing else is changed.
Petros |
Moving together with Petros Stock
0.81 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
0.69 | BKRKF | PT Bank Rakyat | PairCorr |
0.92 | BKRKY | Bank Rakyat | PairCorr |
0.86 | PPERY | Bank Mandiri Persero | PairCorr |
0.72 | PPERF | Bank Mandiri Persero | PairCorr |
0.84 | PBCRY | Bank Central Asia | PairCorr |
0.74 | PTBRY | Bank Negara Indonesia Normal Trading | PairCorr |
0.69 | TRV | The Travelers Companies Financial Report 18th of July 2024 | PairCorr |
0.93 | INTC | Intel Aggressive Push | PairCorr |
0.77 | MCD | McDonalds Financial Report 25th of July 2024 | PairCorr |
0.85 | IBM | International Business Financial Report 17th of July 2024 | PairCorr |
0.94 | HD | Home Depot | PairCorr |
0.72 | CSCO | Cisco Systems Sell-off Trend | PairCorr |
Moving against Petros Stock
0.61 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
0.61 | JPHLF | Japan Post Holdings | PairCorr |
0.59 | JPSTF | JAPAN POST BANK | PairCorr |
0.54 | ROIV | Roivant Sciences Sell-off Trend | PairCorr |
0.92 | GE | GE Aerospace Financial Report 23rd of July 2024 | PairCorr |
0.62 | AXP | American Express Financial Report 19th of July 2024 | PairCorr |
0.56 | DD | Dupont De Nemours Financial Report 7th of August 2024 | PairCorr |
0.55 | KO | Coca Cola Sell-off Trend | PairCorr |
0.45 | PG | Procter Gamble Financial Report 26th of July 2024 | PairCorr |
0.32 | T | ATT Inc Earnings Call Today | PairCorr |
Related Correlations Analysis
0.21 | 0.73 | 0.63 | -0.41 | IDYA | ||
0.21 | 0.04 | 0.5 | 0.38 | ANAB | ||
0.73 | 0.04 | 0.63 | -0.34 | TNYA | ||
0.63 | 0.5 | 0.63 | 0.01 | IGMS | ||
-0.41 | 0.38 | -0.34 | 0.01 | MRUS | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Petros Stock performing well and Petros Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Petros Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
IDYA | 2.06 | (0.26) | 0.00 | (0.12) | 0.00 | 2.74 | 10.88 | |||
ANAB | 3.27 | 0.03 | 0.01 | 0.04 | 4.43 | 11.29 | 25.02 | |||
TNYA | 3.23 | (0.73) | 0.00 | (0.30) | 0.00 | 5.74 | 18.46 | |||
IGMS | 4.68 | (0.41) | 0.00 | (0.58) | 0.00 | 9.57 | 48.77 | |||
MRUS | 2.70 | 0.42 | 0.15 | 0.46 | 2.51 | 6.11 | 44.66 |
Petros Pharmaceuticals Corporate Management
Mitchell MBA | VP Officer | Profile | |
Keith Lavan | Advisor | Profile | |
John Shulman | Executive Board | Profile | |
Robert Weinstein | Interim Officer | Profile |